Companies: 10,795·Total market cap: $144.5T
Palisade Bio, Inc.

Palisade Bio, Inc.

PALINASDAQHealthcare● Active
$1.74
+$0.00(+0.00%)
Market Cap$302028626
P/E Ratio
52W High$2.86
52W Low$0.53
Overview

Palisade Bio, Inc. (PALI) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · PALI · as of Jun 9, 2026

Activity summary

Buy transactions

2

P-Purchase only

Sell transactions

2

12 Months

Buy/Sell ratio

1.00

Buy/Sell (by trades)

Overall sentiment

NEUTRAL
↑ Buy 50%Active transactions only · RSU vesting excluded50% Sell ↓

Palisade Bio, Inc. insiders have shown mixed buying and selling activity over the past 12 Months.

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

PALI insider buying and selling by quarter

PALI insider selling · PALI insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling
19.7M9.9M0
2025 Q1
2025 Q3
2025 Q4
2026 Q1

Mobile shows last 4Q · Desktop shows full 8Q

Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · PALI ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

PALI executive sell shares · PALI board member insider trading · PALI insider trading SEC filing

Showing 6 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Jones Mitchell Lawrence

Chief Medical Officer

Option

Date

Feb 11

Shares

8,000

Price

Value

View Form 4 on SEC.gov

Jones Mitchell Lawrence

Chief Medical Officer

Sale

Date

Feb 12

Shares

1,989

Price

$1.75

Value

$3K

View Form 4 on SEC.gov

Finley John David

CEO, CFO · Director

Option

Date

Feb 11

Shares

13,333

Price

Value

View Form 4 on SEC.gov

Finley John David

CEO, CFO · Director

Sale

Date

Feb 12

Shares

3,896

Price

$1.75

Value

$7K

View Form 4 on SEC.gov

Williams Donald Allen

Director

Purchase

Date

Jan 16

Shares

5,000

Price

$1.67

Value

$8K

View Form 4 on SEC.gov

Williams Donald Allen

Director

Purchase

Date

Jan 9

Shares

5,000

Price

$1.88

Value

$9K

View Form 4 on SEC.gov

Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About PALI insider trading

PALI insider trades

Palisade Bio, Inc. (PALI) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Jones Mitchell Lawrence (Chief Medical Officer), Finley John David (CEO, CFO · Director), Williams Donald Allen (Director). Over the past 12 months, 3 insiders have filed transactions with the SEC. PALI insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Palisade Bio, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic
acquisitionOrDisposition field:
A = Acquisition (buy) · D = Disposition (sell)
RSU vesting (M-Exempt) excluded from sentiment
Form 4SEC filing required within 2 business days of any insider transaction
10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot
Open MktDirect purchase or sale on the open market (excludes awards, options)

Frequently asked questions

PALI insider trading · 5 questions

The insiders of Palisade Bio, Inc. (PALI) include executives and directors such as Jones Mitchell Lawrence (Chief Medical Officer), Finley John David (CEO, CFO · Director), Williams Donald Allen (Director), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

PALI board member insider tradingwho are PALI insidersPALI insider rosterPalisade Bio, Inc. executives insider activity

Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026